(NASDAQ: EXAS) Exact Sciences's forecast annual revenue growth rate of 14.19% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 5.61%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 72.18%.
Exact Sciences's revenue in 2023 is $2,005,096,000.On average, 8 Wall Street analysts forecast EXAS's revenue for 2023 to be $406,822,355,066, with the lowest EXAS revenue forecast at $391,427,809,927, and the highest EXAS revenue forecast at $416,313,703,377.
In 2024, EXAS is forecast to generate $469,860,920,738 in revenue, with the lowest revenue forecast at $458,144,257,522 and the highest revenue forecast at $483,815,869,793.